Acute Coronary Syndrome
Conditions
Brief summary
This is a multicenter, prospective, observational investigation, focusing of antiplatelet treatment in patients with moderate to high risk acute coronary syndrome (TIMI risk score ≥3)subjected to percutaneous coronary intervention (PCI), being conducted in 7 PCI capable hospitals in Greece. Data concerning patients' demographic, clinical/procedural characteristics and contraindications/special warnings and precautions to P2Y12 inhibitors are collected during initial hospitalization. Study involves 3 follow-up visits after hospital discharge(Day 30, at 6 months and at 12 months) where data on major adverse cardiac events (death, myocardial infarction, stroke, urgent revascularization procedure with PCI or CABG), bleeding events(according to Bleeding Academic Research Consortium criteria)and adherence to antiplatelet treatment are collected. In patients under ticagrelor or prasugrel treatment, platelet reactivity measurement with VerifyNow assay will be performed at Day 30
Interventions
None listed
Sponsors
Hellenic Cardiology Society
University of Patras
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age\>18 years * Acute coronary syndrome moderate to high risk (TIMI risk score ≥3) subjected to PCI * Informed consent
Exclusion criteria
* Pregnancy/Breastfeeding * Inability to give informed consent * High probability of being unavailable for follow-up visits
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MACES at 12 months following PCI | 12 months | The composite of death, myocardial infarction, stroke, urgent revascularization procedure with PCI or CABG at 12 months after PCI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Any bleeding event (BARC classification) at 12 months after PCI | 12 months | Any bleeding event (BARC classification) at 12 months after PCI |
Other
| Measure | Time frame | Description |
|---|---|---|
| Rates of P2Y12 inhibitors (Clopidogrel, Prasugrel and Ticagrelor) use at 12 months following PCI | 12 months | Rates of P2Y12 inhibitors (Clopidogrel, Prasugrel and Ticagrelor) use at 12 months following PCI |
| Any bleeding event (BARC classification) at 12 months after PCI | 1 year | Any bleeding event (BARC classification) at 12 months after PCI between lowest and highest quartile of platelet reactivity value at Day 30 |
Countries
Greece
Outcome results
None listed